Dr. Reddy’s Laboratories has unveiled Gilead Sciences’ Remdesivir, an investigational drug used in COVID-19 treatment, under the Redyx brand in India at ₹5,400 per 100mg vial. This follows a licensing pact under which Gilead has granted DRL right to register, manufacture and sell Remdesivir in 127 countries, including India. The Drugs Controller General of India has approved Remdesivir for restricted emergency use in COVID-19 patients hospitalised with severe symptoms. “The launch reaffirms our commitment to bringing in critical medicine for patients suffering from COVID-19 in India,” M.V. Ramana, CEO, Branded Markets (India and Emerging Markets), DRL, said. Dr. Reddy’s thus became one of the few Indian drugmakers to offer Remdesivir and Japanese firm Fujifilm Toyama Chemical’s anti-viral drug Avigan (Favipiravir), which is also used in COVID-19 treatment. Last month it had unveiled Avigan, approved for use in treatment of mild to moderate COVID-19 in India, at ₹99 per tablet.Another release on Wednesday said Dr. Reddy’s had launched over-the-counter Diclofenac Sodium Topical Gel 1%, the store brand version of Voltaren Arthritis Pain in the U.S. market.It partnered with Encube Ethicals to bring to market this product. Terming it an important addition to the company’s pain/analgesics portfolio of OTC products, CEO, North America Generics Marc Kikuchi said the launch “represents our continued commitment to the private label OTC space.” Voltaren is a trademark of Novartis Corporation.Voltaren Arthritis Pain brand had total U.S. retail sales of approximately $44 million since launch in May 2020, the company said.
You have reached your limit for free articles this month.
To get full access, please subscribe.
Already have an account ? Sign in
Show Less Plan
Subscription Benefits Include
Find mobile-friendly version of articles from the day’s newspaper in one easy-to-read list.
Move smoothly between articles as our pages load instantly.
Enjoy reading as many articles as you wish without any limitations.
A one-stop-shop for seeing the latest updates, and managing your preferences.
A select list of articles that match your interests and tastes.
We brief you on the latest and most important developments, three times a day.
*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.
A letter from the Editor
Dear subscriber,Thank you!Your support for our journalism is invaluable. It’s a support for truth and fairness in journalism. It has helped us keep apace with events and happenings.The Hindu has always stood for journalism that is in the public interest. At this difficult time, it becomes even more important that we have access to information that has a bearing on our health and well-being, our lives, and livelihoods. As a subscriber, you are not only a beneficiary of our work but also its enabler.We also reiterate here the promise that our team of reporters, copy editors, fact-checkers, designers, and photographers will deliver quality journalism that stays away from vested interest and political propaganda.Suresh Nambath